For: | Zhang XH, Cao MQ, Li XX, Zhang T. Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World J Hepatol 2020; 12(10): 766-774 [PMID: 33200015 DOI: 10.4254/wjh.v12.i10.766] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v12/i10/766.htm |
Number | Citing Articles |
1 |
Xinhao Wang, Yefa Yang. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases. Medicine 2024; 103(20): e38174 doi: 10.1097/MD.0000000000038174
|
2 |
Yue Ming, Yanqiu Gong, Xuewen Fu, Xinyu Ouyang, Yong Peng, Wenchen Pu. Small-molecule-based targeted therapy in liver cancer. Molecular Therapy 2024; 32(10): 3260 doi: 10.1016/j.ymthe.2024.08.001
|
3 |
Xia Yang, Wenhong Li, Xiaoying Han, Jiao Wang, Jianjian Dai, Xin Ye, Min Meng. Apatinib weakens proliferation, migration, invasion, and angiogenesis of thyroid cancer cells through downregulating pyruvate kinase M2. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-023-50369-w
|
4 |
João Figueira Scarini, Luccas Lavareze, Reydson Alcides de Lima-Souza, Carolina Emerick, Mayara Trevizol Gonçalves, Tayná Figueiredo-Maciel, Gustavo de Souza Vieira, Talita de Carvalho Kimura, Raisa Sales de Sá, Iara Gonçalves Aquino, Patricia Maria Fernandes, Luiz Paulo Kowalski, Albina Altemani, Fernanda Viviane Mariano, Erika Said Abu Egal. Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy. Critical Reviews in Oncology/Hematology 2022; 180: 103863 doi: 10.1016/j.critrevonc.2022.103863
|
5 |
Karthik K Karunakar, Binoy Varghese Cheriyan, Krithikeshvaran R, Gnanisha M, Abinavi B. Therapeutic advancements in nanomedicine: The multifaceted roles of silver nanoparticles. Biotechnology Notes 2024; 5: 64 doi: 10.1016/j.biotno.2024.05.002
|
6 |
Renguo Guan, Chengyou Yu, Shaohua Li, Jie Mei, Wei Wei, Rongping Guo. A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.998534
|
7 |
Lisha Mou, Xiaohe Tian, Bo Zhou, Yongqiang Zhan, Jiao Chen, Ying Lu, Jing Deng, Ying Deng, Zijing Wu, Qi Li, Yi’an Song, Hongyuan Zhang, Jinjun Chen, Kuifeng Tian, Yong Ni, Zuhui Pu. Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.752725
|
8 |
Cuiju Wang, Yalei Lv, Ziyue Sha, Jingjing Zhang, Jianhua Wu, Yixin Qi, Zhanjun Guo. Dicer Enhances Bevacizumab-Related Inhibition of Hepatocellular Carcinoma via Blocking the Vascular Endothelial Growth Factor Pathway. Journal of Hepatocellular Carcinoma 2021; : 1643 doi: 10.2147/JHC.S327258
|
9 |
Shuguang Ju, Wenhui Wang, Pengfei Chen, Fangzheng Li, Hao Li, Manzhou Wang, Xinwei Han, Jianzhuang Ren, Xuhua Duan. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C. Clinics and Research in Hepatology and Gastroenterology 2022; 46(3): 101859 doi: 10.1016/j.clinre.2022.101859
|
10 |
Julu Huang, Rong Liang, Cheng Lu, Lu Lu, Shuanghang Li, Minchao Tang, Xi Huang, Shilin Huang, Rongyun Mai, Xing Gao, Shizhuo Li, Can Zeng, Yan Lin, Jiazhou Ye. A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences 2023; 24(17): 13486 doi: 10.3390/ijms241713486
|
11 |
Feng Zhu, Bi-Rong Wang, Zheng-Feng Zhu, Si-Qin Wang, Chu-Xing Chai, Dan Shang, Min Li. Photodynamic therapy: A next alternative treatment strategy for hepatocellular carcinoma?. World Journal of Gastrointestinal Surgery 2021; 13(12): 1523-1535 doi: 10.4240/wjgs.v13.i12.1523
|
12 |
Hongfang Ma, Na Xing, Lin Hou, Jianhua Wu, Ziyue Sha, Fujun Wang, Xiaohui Ji, Zhanjun Guo. Dicer Inhibits Hepatocellular Carcinoma by Inhibiting the Interleukin 6 Pathway. Hepatitis Monthly 2023; 23(1) doi: 10.5812/hepatmon-134381
|